Processa Pharmaceuticals, Inc. — Regulatory Filings 2021

Jul 15, 2021

8-K 1 form8-k.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 15, 2021

Commission file number 001-39531

PROCESSA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware	45-1539785
(State
or Other Jurisdiction of Incorporation
or Organization)	(I.R.S.
Employer Identification
Number)

| 7380
Coca Cola Drive, Suite 106, Hanover, Maryland 21076 |
| --- |
| (Address
of Principal Executive Offices, Including Zip Code) |

| (443)
776-3133 |
| --- |
| (Registrant’s
Telephone Number, Including Area Code) |

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| [ ] | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| [ ] | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common Stock, $0.0001
par value per share | PCSA | The Nasdaq Stock Market
LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 7.01. Regulation Disclosure.

A copy of a slide presentation (Presentation Materials”) that Processa Pharmaceuticals, Inc. (“Processa Pharmaceuticals”) intends to publish to its website, is attached to this Current Report on Form 8-K and Exhibit 99.1. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Processa Pharmaceuticals may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Processa Pharmaceuticals specifically disclaims any obligation to do so. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

| Exhibit
No. | Exhibit
Description |
| --- | --- |
| 99.1 | Processa
Pharmaceuticals Investor Presentation dated July 2021 |

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on July 15, 2021.

| PROCESSA
PHARMACEUTICALS, INC. | |
| --- | --- |
| Registrant | |
| By: | /s/
David Young |
| | David
Young |
| | Chief
Executive Officer |

Field: Page; Sequence: 3; Options: Last

Field: /Page